PL EN


Preferences help
enabled [disable] Abstract
Number of results
2009 | 59 | 1 | 45-56
Article title

Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy

Content
Title variants
Languages of publication
EN
Abstracts
EN
The cure rates of Helicobacter pylori infection by using a combination of a proton pump inhibitor (PPI) and antimicrobial agents are mainly influenced by bacterial susceptibility to antimicrobial agents and the magnitude of acid inhibition during the treatment. Currently used empirical triple therapies do not reliably produce a 80% cure rate on an intention-to-treat basis. Therefore, tailored regimens based on relevant microbiological findings and pharmacogenomics are recommended for attaining an acceptable 95% cure rate. Recently, virulence factors of H. pylori, such as cagA and vacA, are reported to be major factors determining the cure rates. Individuals infected with strains with cagA-negative and vacA s2 genotypes have significantly increased risk of eradication failure of H. pylori infection. These virulence factors enhance gastric mucosal inflammation and are associated with the development of peptic ulcer and gastric cancer. H. pylori virulence factors induce proinflammatory cytokines, such as interleukin (IL)-1, IL-8, and tumor necrosis factor (TNF)-?, which influence mucosal inflammation and/or gastric acid secretion. When physicians select an H. pylori eradication regimen with an acceptable cure rate, they might need to consider H. pylori virulence factors, especially cagA and vacA.
References
Document Type
REVIEW
Publication order reference
Yoshio Yamaoka, Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Blvd., (111D) Rm 3A-320, Houston, TX 77030, USA
YADDA identifier
bwmeta1.element.element-from-psjc-35502ccc-a575-3d69-9bc8-5823a99ce8d6
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.